AC Immune Announces Safety And Immunogenicity Results Through Week 100 In Part 1 Of VacSYn, Its Phase 2 Trial Of ACI-7104 In Patients With Early-Stage Parkinson’s Disease: All Primary Endpoints Were Met, Generally Safe And Well Tolerated; Strong Immunogenicity Demonstrated, With 100% Response Rate After Three Immunizations
AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced positive safety and immunogenicity results through week-100 in Part
AC Immune tested a new Parkinson's medicine and found it was safe. All patients showed strong immune responses after three doses, which is a good sign.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.